EGFR and non-small cell lung carcinoma: Amplification of CDK4/6 is considered as potential hallmarks for the de novo EGFR tyrosine kinase inhibitor (TKI) resistance in sensitizing EGFR mutation NSCLC (Sitthideatphaiboon et al., 2022).